Recursion Pharmaceuticals, INC Form 4 insider transactions

Christopher Gibson, CEO of Recursion Pharmaceuticals, exercised stock options to acquire 5,000 shares of Class A Common Stock at $2.48 per share on August 30, 2024.

Christopher Gibson, CEO of Recursion Pharmaceuticals, exercised stock options to acquire 5,000 shares of Class A Common Stock at $2.48 per share on August 29, 2024.

Christopher Gibson, CEO of Recursion Pharmaceuticals, exercised stock options to acquire 5,000 shares of Class A Common Stock at $2.48 per share on August 28, 2024.

Christopher Gibson, CEO of Recursion Pharmaceuticals, executed stock options to acquire 5,000 shares of Class A Common Stock at $2.48 per share on August 27, 2024.

Christopher Gibson, CEO of Recursion Pharmaceuticals, executed a transaction involving stock options and Class A Common Stock on August 26, 2024.

Christopher Gibson, CEO of Recursion Pharmaceuticals, exercised stock options to acquire 5,000 shares of Class A Common Stock at $2.48 per share on August 23, 2024.

Director Blake Borgeson of Recursion Pharmaceuticals sold 11,447 shares of Class A Common Stock at an average price of $7.1226 under a pre-arranged 10b5-1 trading plan.

Tina Marriott, President and COO of Recursion Pharmaceuticals, reported the disposal of 14,319 shares of Class A Common Stock to cover tax obligations related to the net settlement of restricted stock units.

David J. Mauro, Chief Medical Officer of Recursion Pharmaceuticals, reports a transaction involving the withholding of shares to cover tax obligations.

Christopher Gibson, CEO of Recursion Pharmaceuticals, reports a transaction involving the withholding of shares to cover tax obligations.

Michael Secora, CFO of Recursion Pharmaceuticals, reports the disposal of 11,962 shares to cover tax obligations related to restricted stock units.

Chief Financial Officer of Recursion Pharmaceuticals, Michael Secora, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Christopher Gibson, CEO of Recursion Pharmaceuticals, executed sales of Class A Common Stock on August 7th and 8th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals (RXRX) at an average price of $6.8213 under a pre-arranged 10b5-1 trading plan.

Najat Khan, Chief R&D Commercial Officer at Recursion Pharmaceuticals, reported the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.

Tina Marriott, President and COO of Recursion Pharmaceuticals, exercised stock options and sold 6,000 shares of Class A Common Stock at an average price of $8.1349, according to a recent SEC Form 4 filing.

Director Blake Borgeson of Recursion Pharmaceuticals sold 11,447 shares of Class A Common Stock on July 23, 2024, under a pre-arranged 10b5-1 trading plan.

CEO Christopher Gibson reports the sale of 100,000 shares of Recursion Pharmaceuticals Class A Common Stock and the conversion of Class B Common Stock into Class A Common Stock.

Christopher Gibson, CEO of Recursion Pharmaceuticals, converted 100,000 shares of Class B Common Stock to Class A Common Stock on June 5, 2024, according to a Form 4/A filing with the SEC.

Michael Secora, CFO of Recursion Pharmaceuticals, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Director Blake Borgeson of Recursion Pharmaceuticals sold 11,447 shares of Class A Common Stock at an average price of $7.315 per share on July 9, 2024, under a pre-arranged 10b5-1 trading plan.

Director Dean Y. Li acquired 1,592 shares of Recursion Pharmaceuticals' Class A Common Stock on July 1, 2024, under the company's Outside Director Compensation Policy.

Director Zavain Dar acquired 1,843 shares of Recursion Pharmaceuticals' Class A Common Stock on July 1, 2024, under the company's Outside Director Compensation Policy.

Director Terry-Ann Burrell acquired 1,843 shares of Recursion Pharmaceuticals' Class A Common Stock on July 1, 2024, under the company's Outside Director Compensation Policy.

Director Blake Borgeson acquired 1,441 shares of Recursion Pharmaceuticals' Class A Common Stock on July 1, 2024, under the company's Outside Director Compensation Policy.

Tina Marriott, President and COO of Recursion Pharmaceuticals, exercised stock options and sold 6,000 shares of Class A Common Stock at an average price of $7.215 per share on June 27, 2024, under a pre-arranged 10b5-1 trading plan.

Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals (RXRX) at an average price of $9.5052 under a pre-arranged 10b5-1 trading plan.

Michael Secora, CFO of Recursion Pharmaceuticals, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock on June 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Christopher Gibson, CEO of Recursion Pharmaceuticals, reported the conversion and sale of Class A Common Stock, as well as transactions related to derivative securities.